Literature DB >> 10586242

Characterization of the effect on adhesion of different mutations in myelin P0 protein.

M T Filbin1, K Zhang, W Li, Y Gao.   

Abstract

Table 1 summarizes the results obtained from expressing in CHO cells C21A P0 and N93A P0 alone, and each with wild-type P0. As can be seen, each of these mutated proteins reach the cell surface when expressed alone, but neither is adhesive. Finally, when each of these mutated P0 molecules is expressed with the wild-type P0, wild-type P0 is no longer adhesive. Therefore, both C21A Po and N93A P0 each have a dominant negative effect on adhesion of wild-type P0. This approach to address the functional consequences of mutations in P0 can now be used to assess the effects of different mutations associated with CMT1B.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10586242

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

Review 1.  Myelin P0: new knowledge and new roles.

Authors:  Joseph Eichberg
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

2.  Novel MPZ mutations and congenital hypomyelinating neuropathy.

Authors:  Hugh J McMillan; Sandro Santagata; Frederic Shapiro; Sat Dev Batish; Libby Couchon; Stephen Donnelly; Peter B Kang
Journal:  Neuromuscul Disord       Date:  2010-11       Impact factor: 4.296

Review 3.  Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.

Authors:  Axel Niemann; Philipp Berger; Ueli Suter
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 4.  Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease.

Authors:  Henry Houlden; Mary M Reilly
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

5.  Implication of the extracellular disulfide bond on myelin protein zero expression.

Authors:  G Pfend; J M Matthieu; N Garin; M Tosic
Journal:  Neurochem Res       Date:  2001-05       Impact factor: 3.996

6.  Four novel mutations of the myelin protein zero gene presenting as a mild and late-onset polyneuropathy.

Authors:  Ilka Kleffner; Anja Schirmacher; Burkhard Gess; Matthias Boentert; Peter Young
Journal:  J Neurol       Date:  2010-06-18       Impact factor: 4.849

Review 7.  Mechanisms and Treatments in Demyelinating CMT.

Authors:  Vera Fridman; Mario A Saporta
Journal:  Neurotherapeutics       Date:  2021-11-08       Impact factor: 6.088

8.  Tracing myelin protein zero (P0) in vivo by construction of P0-GFP fusion proteins.

Authors:  Arif B Ekici; Sevinc Oezbey; Christina Fuchs; Eva Nelis; Christine Van Broeckhoven; Melitta Schachner; Bernd Rautenstrauss
Journal:  BMC Cell Biol       Date:  2002-11-26       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.